Nuclear Medicine: AREVA Selects Caen for Its Future Industrial Development

  Nuclear Medicine: AREVA Selects Caen for Its Future Industrial Development

Business Wire

PARIS -- February 12, 2014

Regulatory News :

Luc Oursel, President of AREVA (Paris:AREVA), announced today, in the presence
of Bernard Cazeneuve, the French Deputy Minister for Finance, Philippe Duron,
Member of Parliament, Mayor of Caen, President of the Caen la Mer urban
community, Jean-Léonce Dupont, Senator, President of the General Council of
Calvados, and Laurent Bauvais, President of the Basse-Normandie Regional
Council, the selection of the Caen la Mer urban community (Calvados, France)
as the location for its second lead-212 production facility.

The future production facility of AREVA Med, the subsidiary dedicated to the
development of cancer treatments, will provide an industrial production
capacity to complement the Maurice Tubiana Facility in Bessines (Haute-Vienne,
France). Based in the Basse-Normandie region, the construction of this
facility will be confirmed following important scientific programs underway.
Lead-212 is a rare metal used in the development of targeted and innovative
treatments for certain cancers that do not respond to other conventional
methods. The first commercial production is planned for 2020.

“This choice illustrates our confidence in the future of AREVA Med and our
determination to create powerful and targeted treatments as quickly as
possible. With its many academic, industrial, and scientific assets, the Caen
la Mer urban community boasts the advantages necessary for the success of our
medical subsidiary. This new project reinforces the historic links between our
group and the Basse-Normandie region,” said Luc Oursel, President and CEO of
AREVA.

Lead-212 is being used currently in a Phase 1 clinical trial coordinated by
AREVA Med at the University of Alabama at Birmingham in the United States.
Several new scientific partnerships are currently being studied with a dozen
institutions.

MORE ABOUT AREVA
AREVA supplies advanced technology solutions for power generation with less
carbon. Its expertise and unwavering insistence on safety, security,
transparency and ethics are setting the standard, and its responsible
development is anchored in a process of continuous improvement.
Ranked first in the global nuclear power industry, AREVA’s unique integrated
offering to utilities covers every stage of the fuel cycle, nuclear reactor
design and construction, and operating services. The group is actively
developing its activities in renewable energies – wind, bioenergy, solar and
energy storage – to become a European leader in this sector.
With these two major offers, AREVA’s 46,000 employees are helping to supply
ever safer, cleaner and more economical energy to the greatest number of
people.

Tour AREVA – 1 Place Jean Millier – 92400 COURBEVOIE – France – Tel: +33 (0)1
34 96 00 00 – Fax: +33 (0)1 34 96 00 01

Contact:

AREVA
Press Office
Julien Duperray
or
Katherine Berezowskyj
or
Aurélie Grange
or
Jérôme Rosso
or
Alexandre Thébault
T: +33 (0)1 34 96 12 15
press@areva.com
or
Investors Relations
Marie de Scorbiac, T: +33 (0)1 34 96 05 97
marie.descorbiac@areva.com
or
Philippine du Repaire, T: +33 (0)1 34 96 11 51
philippine.durepaire@areva.com
 
Press spacebar to pause and continue. Press esc to stop.